. Author manuscript; available in PMC: 2010 Feb 22.

Published in final edited form as: Crit Rev Oncol Hematol. 2008 Aug 15;68(2):172–177. doi: 10.1016/j.critrevonc.2008.06.006

Table 1.

Baseline body composition characteristics (mean ± S.E.)

Parameters	Controls (n = 53)	No ADT (n = 81)	Acute ADT (n = 43)	Chronic ADT (n = 67)	p-Value (across groups)
Age (years)	62.55 ± 1.59	66.70 ± 0.81	70.86 ± 1.19	71.07 ± 1.07	<0.0001
Duration of ADT (months)			2.95 ± 0.25	30.67 ± 3.78
Body mass index (kg/m²)	27.62 ± 0.47	28.26 ± 0.41	28.43 ± 0.88	29.12 ± 0.61	0.3352
Body fat (g)	21629.25 ± 930.57	23606.34 ± 895.82	23999.39 ± 1240.08	27469.28 ± 1129.24	0.0013
Body fat % (% of total mass)	25.14 ± 0.71	26.74 ± 0.66	27.08 ± 0.83	31.43 ± 0.65	<0.0001
Lean body mass (g)	60157.05 ± 884.79	60238.66 ± 771.04	59881.70 ± 1147.27	56482.19 ± 1014.13	0.0092
Lean body mass % (% of total mass)	71.62 ± 0.67	70.25 ± 0.62	69.92 ± 0.79	65.86 ± 0.63	<0.0001
Testosterone (ng/dl)	421.88 ± 24.64	345.5 ± 18.90	81.69 ± 30.65	34.7 ± 12.87	<0.0001
Free testosterone (pg/ml)	66.47 ± 5.00	55.4 ± 3.21	11.64 ± 6.69	2.2 ± 0.38	<0.0001
PSA (ng/ml)	1.8 ± 0.2	1.6 ± 0.3	3.0 ± 1.2	6.2 ± 2.1	0.0219

Abbreviations: ADT, androgen deprivation therapy, PSA, prostate specific antigen.